{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:10:19Z","timestamp":1756289419324,"version":"3.44.0"},"reference-count":12,"publisher":"BMJ","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[1994,5]]},"abstract":"<jats:p>Given by mouth, drugs based on 5-aminosalicylic acid (5-ASA) are often effective in inducing or maintaining remission in patients with ulcerative colitis.1 All of them depend on delaying the release of 5-ASA, so minimising its absorption in the small intestine and maximising delivery to the colon. With sulphasalazine (a chemical combination of 5-ASA and sulphapyridine) and olsalazine (a combination of two molecules of 5-ASA) cleavage of the azo bond by bacteria releases free 5-ASA in the colon. Oral formulations of mesalazine (the approved name for 5-ASA when given alone as a drug) use various physical mechanisms to release the 5-ASA gradually during transit through the gastrointestinal tract. Mesalazine can now be administered directly to the colon as an enema (Pentasa - Yamanouchi Pharma). How effective is this method of administering mesalazine and does it have a specific place in therapy?<\/jats:p>","DOI":"10.1136\/dtb.1994.32538","type":"journal-article","created":{"date-parts":[[2007,10,19]],"date-time":"2007-10-19T11:43:50Z","timestamp":1192794230000},"page":"38-39","source":"Crossref","is-referenced-by-count":0,"title":["A mesalazine enema for ulcerative colitis"],"prefix":"10.1136","volume":"32","member":"239","published-online":{"date-parts":[[1994,5,1]]},"reference":[{"key":"2025082702343114000_32.5.38.1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/dtb.30.13.50","article-title":"Choosing an oral 5-aminosalicylic acid preparation for ulcerative colitis","volume":"30","year":"1992","journal-title":"DTB"},{"key":"2025082702343114000_32.5.38.2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2125.1992.tb04124.x","article-title":"Drug therapy of ulcerative colitis","volume":"34","author":"Crotty","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"2025082702343114000_32.5.38.3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/00365521.1984.12005793","article-title":"5-Aminosalicylic acid enemas in patients with active ulcerative colitis: influence of acidity on the kinetic pattern","volume":"19","author":"Bondesen","year":"1984","journal-title":"Scand J Gastroenterol"},{"key":"2025082702343114000_32.5.38.4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00003088-199120030-00006","article-title":"Retrograde spread of mesalazine (5-aminosalicylic acid)-containing enema in patients with ulcerative colitis","volume":"20","author":"Tiel-van Buul","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"2025082702343114000_32.5.38.5","first-page":"15","article-title":"5-Aminosalicylic acid (Pentasa) in enema form for the treatment of active ulcerative colitis","volume":"18","author":"Willoughby","year":"1986","journal-title":"Ital J Gastroenterol"},{"key":"2025082702343114000_32.5.38.6","first-page":"A195","article-title":"Randomised clinical trial of mesalazine (5-ASA) enemas in distal ulcerative colitis: a dose-ranging placebo controlled study","volume":"96","author":"Hanauer","year":"1989","journal-title":"Gastroenterology"},{"key":"2025082702343114000_32.5.38.7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.8.929"},{"key":"2025082702343114000_32.5.38.8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/BF01296159","article-title":"Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis: a randomised, double-blind multicenter trial","volume":"32","author":"Danish 5-ASA Group","year":"1987","journal-title":"Dig Dis Sci"},{"key":"2025082702343114000_32.5.38.9","first-page":"412","article-title":"5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomised, controlled trial","volume":"81","author":"Friedman","year":"1986","journal-title":"Am J Gastroenterol"},{"key":"2025082702343114000_32.5.38.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6844.35"},{"key":"2025082702343114000_32.5.38.11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0016-5085(88)90569-0","article-title":"5-Aminosalacylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis","volume":"94","author":"Biddle","year":"1988","journal-title":"Gastroenterology"},{"key":"2025082702343114000_32.5.38.12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/dtb.29.17.66","article-title":"Rectal topical corticosteroid preparations","volume":"29","year":"1991","journal-title":"DTB"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.1994.32538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:34:38Z","timestamp":1756287278000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.1994.32538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,5]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[1994,5,1]]},"published-print":{"date-parts":[[1994,5]]}},"alternative-id":["10.1136\/dtb.1994.32538"],"URL":"https:\/\/doi.org\/10.1136\/dtb.1994.32538","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[1994,5]]}}}